Xinjingzhiyuan Biotechnology
A company focusing on the development of TCR-T immune cell therapy drugs for solid tumors.
Launch date
Market cap
-
Enterprise valuation
CAD150—225m (Dealroom.co estimates Mar 2023.)
China (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
* | CNY200m | Series A | |
Total Funding | CAD37.5m |